Safety analysis of luteolin for prostate cancer

Safety analysis of luteolin for patients with prostate cancer receiving active surveilnce. - Safety analysis of luteolin for prostate cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041230029

Enrollment

Registered

2023-05-31

Start date

2023-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer patients

Interventions

Orally taking luteolin 100mg for 24 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) newly diagnosed prostate cancer in low risk patients 2) initial PSA less than 10, and T2 3) patients with informed consent in this research 4) male patients older than 20 5) patients with less than ECOG PS 1

Exclusion criteria

Exclusion criteria: patients in dementia patients with severe infection patients with hepatic dysfunction patients with renal disorders patients who was recognized as inadequate in this test by doctors

Design outcomes

Primary

Measure	Time frame
incidence and severity in adverse events	—

Secondary

Measure	Time frame
PSA or UA response from baseline	—

Contacts

Public ContactTaku Naiki

Nagoya City University Hospital

naiki@med.nagoya-cu.ac.jp+81-52-853-8266

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026